Table 3 The subgroup analysis related to region; the prevalence was examined based on the Courtiers
From: SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis
Regions | Courtiers | Pooled prevalence (95% CI) | Heterogeneity assessment | |
|---|---|---|---|---|
I square | P heterogeneity | |||
America | Overall | 8% (6–11%) | 99.54% | 0.000 |
Brazil | 7% (2–12%) | 90.39% | 0.000 | |
USA | 9% (7–11%) | 93.66% | 0.000 | |
Chile | 11% (9–13%) | – | – | |
Colombia | 29% (31–23%) | – | – | |
European | Overall | 5% (4–6%) | 98.99% | 0.000 |
Belgium | 5% (3–8%) | – | – | |
Croatia | 1% (0–3%) | – | – | |
Denmark | 2% (1–4%) | 68.65% | 0.040 | |
England | 20% (4–45%) | 76.00% | 0.021 | |
Finland | 3% (2–4%) | – | – | |
France | 4% (1–9%) | 87.08% | 0.000 | |
Germany | 7% (0–19%) | 88.68% | 0.000 | |
Greece | 1% (0–2%) | – | – | |
Italy | 5% (3–9%) | 86.58% | 0.000 | |
Spain | 6% (5–7%) | 74.04% | 0.001 | |
Sweden | 5% (4–6%) | 88.00% | 0.000 | |
Switzerland | 8% (5–10%) | – | – | |
Hungary | 1% (1–2%) | – | – | |
Finland | 3% (2–4%) | – | – | |
Croatia | 1% (1–2%) | – | – | |
Luxemburg | 2% (1–3%) | – | – | |
Lithuania | 1% (0–3%) | – | – | |
Western Pacific | Overall | 3% (2–4%) | 96.82% | 0.000 |
China | 2% (1–3%) | 89.91% | 0.000 | |
Japan | 3% (1–5%) | 87.82% | 0.001 | |
Australia | 0% (0–2%) | – | – | |
Korea | 8% (4–12%) | 55.84% | 0.094 | |
Malaysia | 0% (0–2%) | – | – | |
Taiwan | 33% (26–40%) | – | – | |
India | 4% (2–6%) | – | – | |
Eastern Mediterranean | Overall | 15% (5–29%) | 99.09% | 0.000 |
Iran | 15% (12–17%) | – | – | |
Pakistan | 24% (19–39%) | – | – | |
Saudi Arabia | 1% (1–2%) | – | – | |
Africa | Overall | 6% (1–13%) | 97.87% | 0.000 |
Libya | 5% (2–10%) | – | – | |
Kenya | 6% (5–6%) | – | – | |
Togo | 1% (0–2%) | – | – | |
Malavi | 17% (14–20%) | – | – | |